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Background: Postpartum haemorrhage can lead to iron deficiency with and without anaemia, the clinical
consequences of which include physical fatigue. Although oral iron is the standard treatment, it is often associated
with gastrointestinal side effects and poor compliance. To date, no published randomised controlled studies have
compared the clinical efficacy and safety of standard medical care with intravenous administration of iron
supplementation after postpartum haemorrhage.
The primary objective of this study is to compare the efficacy of an intravenous high single-dose of iron isomaltoside
1000 with standard medical care on physical fatigue in women with postpartum haemorrhage.
Methods/Design: In a single centre, open-labelled, randomised trial, women with postpartum haemorrhage exceeding
700 mL will be allocated to either a single dose of 1,200 mg of iron isomaltoside 1000 or standard medical care. Healthy
parturients with a singleton pregnancy will be included within 48 hours after delivery.
Participants will complete structured questionnaires that focus on several dimensions of fatigue and mental health
(Multidimensional Fatigue Inventory, Edinburgh Postnatal Depression Scale and the Postpartum Questionnaire), at
inclusion and at follow-up visits after three days, one week, three weeks, eight weeks, and 12 weeks postpartum. The
primary endpoint is the aggregated change in physical fatigue score within 12 weeks postpartum, as measured by a
subscale of the Multidimensional Fatigue Inventory. The primary objective will be considered to have been met if an
intravenous high single dose of iron isomaltoside 1000 is shown to be superior to standard medical care in women
after postpartum haemorrhage regarding physical fatigue.
For claiming superiority, we set the minimal clinically relevant difference between the mean scores at 1.8, and the
assumed standard deviation at 4.2. Hence, 87 participants per treatment group are needed in order to demonstrate
superiority; to provide an extra margin for missing data and dropouts, 200 women will be included.
Discussion: The study will provide evidence on relevant clinical outcomes beyond biochemical parameters for
intravenous iron isomaltoside 1000 compared to standard medical care in women after postpartum haemorrhage.
Trial registration: This trial is registered with Clinicaltrials.gov (identifier: NCT01895218) on 26 June 2013.
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Postpartum iron deficiency and anaemia
Blood loss of up to 500 mL at delivery is considered
to be a normal physiological mechanism that brings a
woman’s haemoglobin value back to the pre-pregnancy
level [1,2]. Severe postpartum haemorrhage (PPH) is
defined as blood loss above 1,000 mL within the first
24 hours after delivery [3]. Full body iron stores can
replete blood loss up to a maximum of 1,000 mL [4],
which means that many women with a blood loss bet-
ween 500 and 1,000 mL will develop iron deficiency with
or without anaemia. Therefore, in the present study of
iron supplementation, we considered ≥700 mL blood
loss to be the appropriate clinically significant criteria
for inclusion.
Postpartum iron deficiency anaemia may lead to
several clinical consequences, the most prominent of
which is maternal physical fatigue [5]. It is currently
unknown whether treatment can help this fatigue or
whether biochemical markers, such as haemoglobin
(Hb), ferritin and other biomarkers, can measure the
condition and predict clinical treatment effects.
Breastfeeding is important for the health of the infant.
Delayed onset of postpartum lactogenesis increases the
risk of inadequate infant growth and early disconti-
nuation of breastfeeding [6,7]. A retrospective Canadian
study found postpartum iron deficiency anaemia to be
negatively associated with the duration of breastfeeding
[8], but it is unknown whether postpartum iron defi-
ciency anaemia is associated with delayed postpartum
lactogenesis, or if the duration of breastfeeding can be
improved with iron treatment after delivery.
The clinical consequences of postpartum iron defi-
ciency without anaemia are not known in detail.
However, iron deficiency without anaemia in women of
childbearing age is associated with fatigue, impaired
physical work performance, deficient cognitive functions
and mood disturbances [9]. Therefore, it is possible that
postpartum iron deficiency without anaemia contributes
significantly to physical fatigue in the puerperium, and
that iron treatment is beneficial for these women and
their infants.
Intravenous iron
The currently available intravenous iron preparations are
generally considered equally efficacious but vary in terms
of molecular size, kinetics, bioavailability and toxicology
[10,11]. The European Medicines Agency recently re-
viewed the safety of intravenous iron. It concluded that
the benefits of intravenous iron are greater than their
risks and was unable to establish a difference in the
safety profiles of the products [12].
Isomaltoside 1000, the carbohydrate component in iron
isomaltoside 1000 (Monofer®), has a mean molecularweight of 1,000 Da and consists predominantly of three to
five glucose units. The carbohydrate isomaltoside is linear
and unbranched with a low immunogenic potential. Iron
isomaltoside 1000 has strongly bound iron within the iron
isomaltoside formulation, which enables a controlled slow
release of bioavailable iron to the iron-binding proteins
with minimal risk of free iron toxicity [13].
To date, iron isomaltoside 1000 has been approved in
Europe for the treatment of iron deficiency anaemia.
The indications are when oral iron preparations are
ineffective or cannot be used, or where there is a clinical
need to deliver iron rapidly. Several studies of iron
isomaltoside 1000 treatment of iron deficiency anaemia
have been published, including the use of bolus injec-
tions and high single-dose infusions, without detected
unexpected safety issues [14-17].
Iron isomaltoside 1000 was chosen for this study as it
is approved for high single dosing of up to 20 mg/kg.
The high single dose is preferable in the treatment of
puerperal women, as they need fast correction of their
iron deficit before leaving the hospital.
Previous studies and current guidelines
International guidelines are available for the treatment
of iron deficiency anaemia in pregnancy and the postpar-
tum period [18-21]. These guidelines recommend oral
iron supplementation in mild anaemia, intravenous iron
in moderate anaemia and when oral iron supplementa-
tion is not tolerated, and allogeneic red blood cell (RBC)
transfusion in severe and symptomatic cases. These
guidelines do not deal with screening for or treatment of
iron deficiency without anaemia.
Denmark has no published national guideline on the
screening or treatment of postpartum iron deficiency
with or without anaemia. In clinical practice, doctors
usually recommend oral iron supplementation to partu-
rients with PPH, and RBC transfusion to those with se-
vere symptoms of anaemia. Since puerperal women with
a Hb level of ≤6.5 g/dL (4.0 mmol/L) often have severe
symptoms of anaemia, we will not include these partu-
rients in the study.
No prospective randomised clinical studies have yet
assessed the effect of intravenous iron supplementation in
comparison to standard medical care in women after PPH
with a clinical outcome as the primary endpoint. There
have been 10 randomised controlled studies that have
compared intravenous iron to oral iron supplementation
in women with diagnosed postpartum iron deficiency an-
aemia [22-31]. The inclusion criteria of these studies were
Hb concentration up to 10 days after delivery, and the pri-
mary study endpoints were Hb concentration, iron para-
meters and comparisons thereof. Generally, these studies
have demonstrated improvement of Hb and iron parame-
ters, favouring intravenous iron. With regard to safety,
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in up to 30% of the participants, with a compliance rate as
low as 50%. These findings must be balanced against the
very low risk of severe hypersensitivity reactions with
intravenous iron [12].
Hb concentration and other biochemical parameters
are influenced by the haemodynamic changes, and are
therefore considered unreliable for diagnosing iron defi-
ciency anaemia in the first week(s) after giving birth
[32]. However, it is crucial that these women can benefit
from treatment in the clinically important first days after
delivery. In the present study, we have chosen to include
women based on their clinically estimated blood loss
after delivery, and we hypothesise that women with
clinically significant PPH will have an increased risk of
developing iron deficiency with or without anaemia.
We believe that iron treatment should be administered
in order to improve clinical symptoms of iron deficiency
with or without anaemia, not just to improve bio-
chemical markers. This is in accordance with a syste-
matic review, which concluded that there is a lack of
high-quality studies with clinical outcomes [33]. There-
fore, we have decided that the primary outcome in the
present study will be a clinically significant improvement
in the physical fatigue score between the treatment
groups. We hypothesise that intravenous iron is superior
to standard medical care.
Objective
The primary objective of this study is to compare the
efficacy of intravenous high single doses of iron isomal-
toside 1000 to standard medical care on physical fatigue
in women with PPH.
Methods/Design
Study design
The study will be a randomised, comparative, open-label
single-centre study with a 1:1 allocation ratio. The trial
is a company-sponsored interventional trial conducted
according to International Conference on Harmonization-
Good Clinical Practice (ICH-GCP) guidelines [34].
Inclusion criteria
Women, regardless of mode of delivery, will be eligible
for inclusion in the study if they fulfil the following
criteria: (1) they have signed the informed consent form,
and (2) they have either (a) PPH ≥700 and ≤1,000 mL or
(b) PPH >1,000 mL and Hb >6.5 g/dL (4.0 mmol/L)
measured at >12 hours after delivery (Figure 1).
Exclusion criteria
Exclusion criteria: age <18 years; multiple births; peripar-
tum RBC transfusion; known iron overload or disturbances
in the utilisation of iron (such as haemochromatosis orhaemosiderosis); known hypersensitivity to parenteral iron
or any excipients in the investigational drug products; a
history of active asthma within the previous five years; a
history of multiple allergies; known decompensated liver
cirrhosis or active hepatitis; haemolysis, elevated liver
enzymes, and low platelet count (HELLP) syndrome; active
acute infection (clinical symptoms or fever above 38.5°C);
rheumatoid arthritis; history of anaemia caused by a known
haematological disorder other than iron deficiency; in-
ability to read, speak and understand the Danish language;
participation in any other clinical study where the study
drug has not passed five half-lives prior to the baseline and
any other medical condition that, in the opinion of the
investigator, may cause the parturient to be unsuitable for
completion of the study or place her at potential risk from
participating in the study.
Randomisation
Participants will be randomised using an interactive
web response system (eClinical OS™, Merge Healthcare,
Morrisville, NC, United States). The randomisation lists
will be prepared centrally by the contract research
organization BioStata ApS, Birkerød, Denmark using a
validated computer program. The randomisation will be
stratified by bleeding volume (PPH: 700 to 1,000 mL or
PPH >1,000 mL). Within each bleeding category, there
will be a 1:1 randomisation ratio to one of the two
treatment groups.
Intervention
The participants will be randomised to either standard
medical care or iron isomaltoside 1000. Standard medical
care (current treatment practice) at the Department of
Obstetrics, Copenhagen University Hospital, Rigshospitalet
is typically to recommend women with PPH to either con-
tinue oral iron supplementation, as during pregnancy (the
Danish Health and Medicines Authority recommends 40
to 50 mg oral iron supplementation daily [35]), or to take
100 mg oral iron one or two times daily for a variable time
period. The actual use of iron supplementation, including
specific preparation, dose and duration of treatment, will
be monitored at each follow-up visit.
Immediately after acute bleeding such as PPH, the Hb
level is inaccurate for calculating individual dosing of
iron supplementation. Hence, the iron isomaltoside 1000
fixed dosage in this study is based on the expected iron
deficiency in women after PPH. Body iron stores are
approximately 500 to 750 mg and the average iron loss
through PPH is approximately 500 mg, as 500 mL blood
loss equals 250 mg iron loss [4]. In previous studies of
women with postpartum anaemia, oral iron treatment
dosages were 130 to 200 mg per day over a period of 42 to
84 days, resulting in a total average dose of 11.088 mg
[23-27]. The intestinal iron absorption varies considerably
Figure 1 Trial flow. Women with postpartum haemorrhage ≥700 and ≤1,000 mL or PPH >1,000 mL and haemoglobin >6.5 g/dL (4.0 mmol/L)
within 48 hours of delivery will be screened for inclusion and exclusion and asked for consent to participate. Baseline questionnaires are
completed and blood samples are taken. The participants are randomised to either intravenous iron isomaltoside 1000 or standard medical care.
Follow-up visits with completion of questionnaires, blood samples and maternal milk samples are performed at three days, and one, three, eight
and 12 weeks after intervention. (EPDS: Edinburgh Postnatal Depression Scale; Hb: haemoglobin; HELLP: haemolysis, elevated liver enzymes, and
low platelet count; MFI: Multidimensional Fatigue Inventory; PPH: postpartum haemorrhage; PPQ: Postpartum Questionnaire; RBC: red blood cells;
subMFI: subscale of the Multidimensional Fatigue Inventory; subPPQ: subscale of the Postpartum Questionnaire).
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a total expected absorption of 1,100 to 1,200 mg. Thus,
the cumulated iron dosages in these studies are in accor-
dance with the chosen treatment dose in this study.
In the group allocated to iron isomaltoside 1000,
Pharmacosmos A/S, Holbaek, Denmark, the iron re-
placement dose is set to 1,200 mg. The dose is diluted in
100 mL 0.9% sodium chloride, Fresenius Kabi AG, BadHomburg, Germany, and administered over a period of
approximately 15 minutes. No test dose is applied. Par-
ticipants with a pre-pregnancy weight <45 kg will receive
a reduced single dose of 1,000 mg iron isomaltoside
1000, administered in the same fashion. In both treat-
ment groups, participants may be given a ‘rescue’ allo-
geneic RBC transfusion if this procedure is clinically
indicated.
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The parturients will be screened for inclusion in the study
over an 18-month period at the Department of Obstetrics,
Copenhagen University Hospital, Rigshospitalet, a tertiary
hospital that performs between 6,000 and 7,000 deliveries
per year. Eligible parturients are informed about the study
and must provide their written consent within 48 hours
after delivery. The duration for each individual participant
is approximately 12 weeks and involves five follow-up
visits by a midwife at the participant’s home. The time-
frames of the follow-up visits are three days (between two
and four days), one week (between six and eight days),
three weeks (between 19 and 23 days), eight weeks
(between seven and nine weeks) and 12 weeks (between
11 and 13 weeks).
Outcomes and safety measures
The primary outcome is the aggregated change in phys-
ical fatigue score within 12 weeks postpartum, as mea-
sured by a subscale of the Multidimensional Fatigue
Inventory (MFI) [37]. Secondary efficacy outcomes in-
clude changes in the Hb concentration, p-ferritin, p-iron,
p-transferrin, transferrin saturation, reticulocyte count,
mean reticulocyte Hb content, other MFI and Postpar-
tum Questionnaire (PPQ) fatigue items, symptoms of
postpartum depression, time of postpartum lactogenesis,
time of discontinuation of breastfeeding and transfusion
of allogeneic RBCs.
The safety outcomes are discontinuation due to intoler-
ance, frequency, nature and severity of adverse events, vital
signs, and p-sodium, p-potassium, p-calcium, p-phosphate,
p-urea, p-creatinine, p-albumin, p-bilirubin, p-aspartate
aminotransferase and p-alanine aminotransferase levels.
Other outcomes are maternal milk iron level, anaemia
symptoms and gastrointestinal symptoms.
Questionnaires
We will use the three following self-reported question-
naires: the fatigue measures MFI and PPQ and the de-
pression measure Edinburgh Postnatal Depression Scale
(EPDS) [38]. Of these, the MFI includes the scale of
physical fatigue, which is the primary endpoint of this
investigation.
The MFI has been found to have high feasibility,
reliability and validity in chronically anaemic women
[39] and in postpartum women [40]. The MFI covers the
following dimensions: general fatigue, physical fatigue,
reduced activity, reduced motivation and mental fatigue.
The MFI consists of 20 statements for which the partici-
pant indicates, on a five-point scale, the extent to which
the particular statement applies to her. The statements
refer to aspects of fatigue experienced during the pre-
vious days. Higher scores indicate a higher degree of
fatigue.The PPQ is a novel and yet to be validated instrument
that was developed for this study to measure fatigue in
parturients [see Additional file 1 (in Danish)]. It consists
of a visual analogue scale of how tired the participant is
and five questions regarding fatigue. The first question
concerns what the participant experiences as most
troublesome, pain or fatigue. The second question con-
cerns whether the fatigue is experienced most physically
or mentally. For each of the first two questions the
participant is asked to underline one of five possible
responses. The last three questions explore how the
fatigue influences breastfeeding, contact with the new-
born and to what extend the participant asks for help
with nappy changing. The participant is asked to indi-
cate, on a four-point scale, the extent of the influence of
the fatigue. Higher scores from the last three questions
indicate a higher degree of fatigue.
The EPDS is a screening instrument that was deve-
loped to detect symptoms of depression in puerperal
women. A number of studies have confirmed that the
EPDS is both reliable and sensitive [41]. The EPDS con-
sists of 10 questions. Participants are asked to underline
one of four possible responses that comes closest to how
she has been feeling during the previous seven days. The
maximum score is 30 and a score of 10 or higher
indicates possible depression.
Monitoring and data collection
The data collection tool for this study is an electronic
case report form. Data necessary for analyses and
reporting will be entered into a validated and secured
data system. Clinical data management is performed in
accordance with applicable standards and data cleaning
procedures.
A clinical research associate (CRA) from a contract
research organisation will monitor the study for protocol
compliance, verifying that safety procedures and the rights
of participants are being protected. The CRA will also
verify that the study is conducted in accordance with the
currently approved protocol and any other study agree-
ments, ICH-GCP guidelines and all applicable regulatory
requirements. The CRA will also monitor and verify that
data are authentic, accurate and complete.
Number of participants
The following hypothesis will be tested: iron isomal-
toside 1000 is superior to standard medical care in the
treatment of iron deficiency in women with PPH with or
without anaemia, measured primarily by a reduction in
physical fatigue. The null hypothesis of no difference
between the treatment groups will be tested against the
alternative by constructing a two-sided 95% confidence
interval of the difference in aggregated change in phy-
sical fatigue score from baseline to week 12 between the
Holm et al. Trials 2015, 16:5 Page 6 of 8
http://www.trialsjournal.com/content/16/1/5two treatment groups. The sample size calculations are
based on the primary endpoint, aggregated change in
physical fatigue score from baseline to week 12. A two-
sided significance level of 5% is used and the power is
set to 80%.
The use of the physical fatigue subscale of MFI allows
a maximum change of 16 points. Based on clinical
judgement and consensus between all authors, we wish
to see a difference greater than 10% for claiming clini-
cally relevant superiority. Hence, we set the minimal
clinically relevant difference to 1.8. In a previous study,
the standard deviation was found to be approximately
4.2 [40]. Therefore, 87 patients per treatment group are
needed in order to demonstrate superiority. With a
margin for missing data and a dropout rate of 13%, 200
women will be included.
Statistical methods and data analysis
All tests are pre-specified in a statistical analysis plan.
The primary analysis population will be the full analysis
set, including all randomised participants who received
the study drug and have at least one post-baseline phy-
sical fatigue score. The primary endpoint is the aggre-
gated change in the physical fatigue score from baseline
to week 12. This will be calculated as the area under the
curve of the changes in the physical fatigue score from
baseline to each visit until week 12, divided by the
number of scheduled days (observation period). The area
under the curve will be calculated using the linear
trapezoidal method and scheduled days. The primary
endpoint will be analysed using an analysis of variance
model, with treatment and amount of PPH (700 to
1,000 mL or >1,000 mL) as factors, and baseline MFI
physical fatigue score as the covariate. The estimated
treatment differences (iron isomaltoside 1000 versus
standard medical care) expressed as contrasts of the ad-
justed means will be presented with corresponding 95%
confidence intervals and the P value. Iron isomaltoside
1000 will be considered superior to standard medical
care if the lower limit of the 95% confidence interval is
above zero. We will also perform a per protocol analysis
excluding participants with major protocol deviations,
such as rescue allogeneic RBC transfusion.
All statistical tests of the efficacy endpoints will be
two-sided and performed on a 5% significance level.
Estimated treatment differences and 95% confidence
limits will be presented together with the corresponding
P value. Continuous secondary endpoints will be ana-
lysed by a mixed model for repeated measurements,
including visit and treatment-by-visit, and PPH (700 to
1,000 mL or >1,000 mL) as factors, the baseline value as
the covariate, and the subject as the random effect. If no
baseline value is measured for the endpoint in question,
the value at the first measured time will be included asthe covariate. An unstructured covariance structure
will be used to model the within-subject errors and
the estimation method will be a restricted maximum
likelihood-based approach. The analysis will be based on
the ‘missing at random’ assumption and performed using
the data from each observed case. ‘Proportion’ endpoints
will be analysed by logistic regression with treatment as
the factor. Where relevant, the baseline value of the
parameter in question will be included as the covariate.
Time to postpartum lactogenesis and time to discon-
tinuation of breastfeeding will be assessed and analysed
using Kaplan-Meier curves and compared between treat-
ments using a log-rank test. The laboratory data will be
analysed as described for the continuous variables above.
Adverse events will be summary tabulated using the
latest version of the Medical Dictionary for Regulatory
Activities body system and preferred term indicating the
number and percentage of participants and the number
of events. The number of participants who experience
an adverse drug reaction, including suspected unexpec-
ted serious adverse reactions, will be compared between
treatment groups.
Consent and ethical considerations
Women planning to give birth at the Department of
Obstetrics, Copenhagen University Hospital, Rigshospitalet
have received written information about the study at one
of their antenatal midwife consultations. When a par-
turient fulfils the inclusion criteria, she will be asked to
participate in the study after receiving oral and written
information from an investigator. In obtaining and docu-
menting informed consent, the investigator will comply
with any applicable regulatory requirements, and will
adhere to ICH-GCP and the Declaration of Helsinki. The
National Committee on Biomedical Research Ethics (ap-
proval number: H-4-2013-019) and the Danish Medicines
Agency (approval number: EudraCT 2012-005782-12)
have approved the study. The trial is registered at Clinical-
trials.gov (identifier: NCT01895218).
Discussion
The aim of this study is to compare a new treatment op-
tion (iron isomaltoside 1000) to standard medical care.
The choice of the latter active comparator, ‘the drug of
first choice’, enables us to use the results of this study for
assessing the potential additional benefit of iron isomal-
toside 1000 in a clinical setting.
The standard medical care treatment group does not
receive a general specified recommendation of oral iron
supplementation. We considered that standard treat-
ment, as defined by the individualised regimen chosen
by the parturient and her midwife, was the proper
comparator. A pregnant woman usually takes oral iron
supplementation from early pregnancy and finds a
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fixed regimen might cause gastrointestinal side effects
in some individuals, and a possible insufficient effect
in others. Therefore, the fixed regimen would be sub-
optimal as a comparator compared with the standard
individualised regimen, which is current practice in the
Capital Region of Denmark. The actual use of oral iron,
including specific preparation, dose and duration of
treatment, is registered at each follow-up visit.
The individualised regimen design implies that we
were not able to blind the randomisation in this trial.
Also, since iron tablets colour the stools, we assessed
that a double-blinded design would be unfeasible and
would not contribute additional scientific merit. Accor-
dingly, most previously published randomised controlled
trials with iron treatment of women after childbirth have
not been double-blinded [23-27].
The strength of this trial is the fact that it will be con-
ducted at a single centre. This means that the standard
medical care is less diverse than it might otherwise be
and we can ensure a full overview of all parturients with
PPH ≥700 mL in the time period of inclusion, which will
enable us to collect detailed information about those
excluded and the reasons why not.
The risk of bias by selecting the subjective endpoint
physical fatigue in an open-label study is an inherent
weakness of the study. Fatigue is an important clinical
endpoint that has consistently been shown to be affected
by iron deficiency and iron deficiency anaemia. However,
fatigue in the postpartum period is highly dependent on
various attributes, including the mode and outcome of
delivery, the duration of labour, medical comorbidities,
the health of the infant and a host of social and environ-
mental factors. Nevertheless, this design was previously
used in a randomised controlled study in a similar
population, where an open-label design and subjective
primary endpoint were chosen for the most clinically
relevant design [42].
The instrument used for measuring the primary
endpoint is the physical fatigue subscale of the MFI. We
selected this instrument due to its previous validation,
including the findings of high feasibility and reliability in
the postpartum population, specifically its use for mea-
suring fatigue in parturients that experienced PPH. How-
ever, no validated questionnaires have been specifically
developed for measuring postpartum fatigue. Although
some available questionnaires for measuring fatigue have
been validated for this population, they are all constructed
to measure fatigue in other populations, often cancer or
other chronic ill patients. Therefore, we developed a new
questionnaire (PPQ) that is designed specifically to mea-
sure fatigue among puerperal women. A further objective
of this study is to assess and validate its ability to measure
fatigue in women after PPH.Trial status
The trial was initiated and the first parturient was
included in May 2013. Inclusion and randomisation are
ongoing and expected to be finished in August 2014.
Additional file
Additional file 1: Postpartum Questionnaire.
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